021 Understanding Risk in Myeloma: What Your Genetics Can Tell You

This episode unpacks the complex world of myeloma genetics - what high and standard risk really mean, how these tests guide treatment, and how future advances could lead to truly personalised care with Sarah Gooding. Sarah is a colleague, and an Honorary Consultant Haematologist, based in Oxford.   📌Key Takeaways: Your myeloma is unique - genetic tests help doctors understand how it may behave and respond to treatment. High-risk myeloma can still respond well to newer, more powerful therapies now being developed. The future lies in personalised treatment - matching the right drug to each patient’s myeloma for the best outcomes. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.